FGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Brunello, Eleonora ^a   Brunelli, Matteo ^a   Bogina, Giuseppe ^b   Caliò, Anna ^a   Manfrin, Erminia ^a   Nottegar, Alessia ^a   Vergine, Marco ^c   Molino, Annamaria ^d   Bria, Emilio ^d   Massari, Francesco ^d   Tortora, Giampaolo ^d   Cingarlini, Sara ^d   Pedron, Serena ^a   Chilosi, Marco ^a   Zamboni, Giuseppe ^a,b   Miller, Keith ^e   Martignoni, Guido ^a   Bonetti, Franco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY HOSPITAL OF VERONA   (Italy)

^e United Kingdom National External Quality Assessment Service   (United Kingdom)

Author keywords

FGFR 1 amplification; In situ hybridization; Lobular breast carcinoma; Metastases

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR 1; UVOMORULIN;

ARTICLE; BREAST CARCINOMA; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LOBULAR BREAST CARCINOMA; METASTASIS; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CADHERINS; CARCINOMA, LOBULAR; DNA TOPOISOMERASES, TYPE II; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LYMPH NODES; LYMPHATIC METASTASIS; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; TUMOR MARKERS, BIOLOGICAL;

EID: 84871580550     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-103     Document Type: Article

References (33)

1. International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the fourth symposium on primary systemic therapy in the management of operable breast cancer, Cremona, Italy (2010). Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, et al. J Natl Cancer Inst Monogr 2011 2011 147 151 10.1093/jncimonographs/lgr037 22043063
2. Classical lobular breast carcinoma consistently lacks topoisomerase-IIalpha gene amplification: implications for the tailored use of anthracycline-based chemotherapies. Brunello E, Brunelli M, Manfrin E, Nottegar A, Bersani S, Vergine M, Molino A, Fiorio E, Chilosi M, Gobbo S, Martignoni G, Bonetti F, Histopathology 2012 60 482 488 10.1111/j.1365-2559.2011.04067.x 22168383
3. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting. Vergine M, Brunelli M, Martignoni G, Brunello E, Miller K, Pecori S, Bersani S, Chilosi M, Menestrina F, Manfrin E, Bonetti F, Histopathology 2010 57 935 940 21166708
4. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. Cristofanilli M, Gonzalez-Angulo A, Sneige N, Kau SW, Broglio K, Theriault RL, Valero V, Buzdar AU, Kuerer H, Buccholz TA, Hortobagyi GN, J Clin Oncol 2005 23 41 48 15625359 (Pubitemid 41702621)
5. Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, Narasimhan NI, Shakespeare WC, Wang F, Clackson T, Rivera VM, Mol Cancer Ther 2012 11 690 699 10.1158/1535-7163.MCT-11-0450 22238366
6. Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors. Patel RR, Sengupta S, Kim HR, Klein-Szanto AJ, Pyle JR, Zhu F, Li T, Ross EA, Oseni S, Fargnoli J, Jordan VC, Eur J Cancer 2010 46 1537 1553 10.1016/j.ejca.2010.02.018 20303261
7. FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Reis-Filho JS, Simpson PT, Turner NC, Lambros MB, Jones C, Mackay A, Grigoriadis A, Sarrio D, Savage K, Dexter T, et al. Clin Cancer Res 2006 12 6652 6662 10.1158/1078-0432.CCR-06-1164 17121884 (Pubitemid 44876833)
8. Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. Ayers M, Fargnoli J, Lewin A, Wu Q, Platero JS, Cancer Res 2007 67 6899 906 10.1158/0008-5472.CAN-06-4555 17638901 (Pubitemid 47105537)
9. A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer. Andre F, Bachelot TD, Campone M, Dalenc F, Perez-Garcia JM, Hurvitz SA, Turner NC, Rugo HS, Shi MM, Zhang Y, Kay A, Yovine AJ, Baselga J, J Clin Oncol 2011 508 uppl 508
10. Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Koziczak M, Holbro T, Hynes NE, Oncogene 2004 23 3501 3508 10.1038/sj.onc.1207331 15116089 (Pubitemid 38658416)
11. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: impact on selecting patients for herceptin therapy. Brunelli M, Manfrin E, Martignoni G, Bersani S, Remo A, Reghellin D, Chilosi M, Bonetti F, Am J Clin Pathol 2008 129 907 911 10.1309/MD79CDXN1D01E862 18480007
12. Current and emerging targeted therapies for metastatic breast cancer. Perez EA, Spano JP, Cancer 2012 118 3014 25 10.1002/cncr.26356 22006669
13. Novel agents in the era of targeted therapy: what have we learned and how has our practice changed? Baselga J, Ann Oncol 2008 19 Suppl 7 22ii281 vii288 18790967
14. The fibroblast growth factor receptor 1 (FGFR1), a marker of response to chemoradiotherapy in breast cancer? Massabeau C, Sigal-Zafrani B, Belin L, Savignoni A, Richardson M, Kirova YM, Cohen-Jonathan-Moyal E, Mégnin-Chanet F, Hall J, Fourquet A, Breast Cancer Res Treat 2012 134 259 266 10.1007/s10549-012-2027-3 22438050
15. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, Lopez-Garcia MA, Natrajan R, Marchio C, Iorns E, Mackay A, et al. Cancer Res 2010 70 2085 2094 10.1158/0008-5472.CAN-09-3746 20179196
16. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, Chande A, Tanaka KE, Stransky N, Greulich H, et al. PLoS One 2011 6 20351 10.1371/journal.pone.0020351 21666749
17. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, et al. N Engl J Med 2012 366 883 892 10.1056/NEJMoa1113205 22397650
18. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, Zeillinger R, Rodriguez C, Theillet C, Cancer Res 1997 57 4360 4367 9331099 (Pubitemid 27413447)
19. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis. Kwek SS, Roy R, Zhou H, Climent J, Martinez-Climent JA, Fridlyand J, Albertson DG, Oncogene 2009 28 1892 1903 10.1038/onc.2009.34 19330026
20. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1. Karlsson E, Waltersson MA, Bostner J, Perez-Tenorio G, Olsson B, Hallbeck AL, Stal O, Genes Chromosomes Cancer 2011 50 775 787 10.1002/gcc.20900 21748818
21. Comprehensive profiling of 8p11-12 amplification in breast cancer. Gelsi-Boyer V, Orsetti B, Cervera N, Finetti P, Sircoulomb F, Rouge C, Lasorsa L, Letessier A, Ginestier C, Monville F, et al. Mol Cancer Res 2005 3 655 667 10.1158/1541-7786.MCR-05-0128 16380503 (Pubitemid 43042995)
22. Translocation and coamplification of loci from chromosome arms 8p and 11q in the MDA-MB-175 mammary carcinoma cell line. Adelaide J, Chaffanet M, Mozziconacci MJ, Popovici C, Conte N, Fernandez F, Sobol H, Jacquemier J, Pebusque M, Ron D, et al. Int J Oncol 2000 16 683 688 10717235
23. Expression of the FGFR1 gene in human breast-carcinoma cells. Jacquemier J, Adelaide J, Parc P, Penault-Llorca F, Planche J, deLapeyriere O, Birnbaum D, Int J Cancer 1994 59 373 378 10.1002/ijc.2910590314 7927944 (Pubitemid 24331829)
24. FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Elbauomy Elsheikh S, Green AR, Lambros MB, Turner NC, Grainge MJ, Powe D, Ellis IO, Reis-Filho JS, Breast Cancer Res 2007 9 23 10.1186/bcr1665 17397528 (Pubitemid 350215164)
25. Differential expression assay of chromosome arm 8p genes identifies Frizzled-related (FRP1/FRZB) and Fibroblast Growth Factor Receptor 1 (FGFR1) as candidate breast cancer genes. Ugolini F, Adelaide J, Charafe-Jauffret E, Nguyen C, Jacquemier J, Jordan B, Birnbaum D, Pebusque MJ, Oncogene 1999 18 1903 1910 10.1038/sj.onc.1202739 10086345 (Pubitemid 29145858)
26. Fibroblast growth factor receptors in breast cancer: expression, downstream effects, and possible drug targets. Tenhagen M, van Diest PJ, Ivanova IA, van der Wall E, van der Groep P, Endocr Relat Cancer 2012 19 115 29 10.1530/ERC-12-0060 22508544
27. Fibroblast growth factor receptor 1-transformed mammary epithelial cells are dependent on RSK activity for growth and survival. Xian W, Pappas L, Pandya D, Selfors LM, Derksen PW, de Bruin M, Gray NS, Jonkers J, Rosen JM, Brugge JS, Cancer Res 2009 69 2244 2251 10.1158/0008-5472.CAN-08-3398 19258500
28. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Gavine PR, Mooney L, Kilgour E, Thomas AP, Al-Kadhimi K, Beck S, Rooney C, Coleman T, Baker D, Mellor MJ, Brooks AN, Klinowska T, Cancer Res 2012 72 2045 2056 10.1158/0008-5472.CAN- 11-3034 22369928
29. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Shiang CY, Qi Y, Wang B, Lazar V, Wang J, Fraser Symmans W, Hortobagyi GN, Andre F, Pusztai L, Breast Cancer Res Treat 2010 123 747 755 10.1007/s10549-009-0677-6 20024612
30. FGFR1 amplification and the progression of non-invasive to invasive breast cancer. Gru AA, Allred DC, Breast Cancer Res 2012 14 116 10.1186/bcr3340 23151501
31. Discordant cellular response to presurgical letrozole in bilateral synchronous ER + breast cancers with a KRAS mutation or FGFR1 gene amplification. Balko JM, Mayer IA, Sanders ME, Miller TW, Kuba MG, Meszoely IM, Wagle N, Garraway LA, Arteaga CL, Mol Cancer Ther 2012 11 2301 2305 10.1158/1535-7163.MCT-12-0511 22879364
32. FGFR1 is amplified during the progression of in situ to invasive breast carcinoma. Jang MH, Kim EJ, Choi Y, Lee HE, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY, Breast Cancer Res 2012 14 115 10.1186/bcr3239 22863309
33. Molecular differences between ductal carcinoma in situ and adjacent invasive breast carcinoma: a multiplex ligation-dependent probe amplification study. Moelans CB, de Wegers RA, Monsuurs HN, Maess AH, van Diest PJ, Cell Oncol (Dordr) 2011 34 475 482